FDA approves MAVYRET™, the first treatment for all genotypes of hepatitis C approved by this US agency for pediatric use. On behalf of Canada’s children, we hope Canada will soon follow (Canada’s version of AbbVie’s hepatitis C drug is spelled Maviret™)!

For Immediate Release, April 30, 2019

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-all-genotypes-hepatitis-c-pediatric-patients